Link to full article Melbourne, Australia – 7 March 2022: Adherium (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces the submission to the US Food and Drug Administration (FDA) of a 510(k) clearance to market application to connect Ellipta® inhaler users with its new, next generation Hailie® sensor with […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-03-08 01:29:352022-03-08 01:31:02Adherium submits US FDA 510(k) application for Ellipta® inhaler users to connect to Hailie platform with physiological parameters
Link to Full Article Melbourne, Australia – 25 February 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, announces the appointment of Mr Lou Panaccio as a Non-executive director of Adherium with Mr Matthew McNamara stepping down as a […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-03-08 01:14:502022-03-08 01:14:50Adherium announces the appointment of Lou Panaccio to the Board with Matt McNamara stepping down
Link to article Melbourne, Australia – 11 February 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce it has completed the first production run of the next generation Hailie® sensors with physiological parameters for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD) medication use. […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2022-03-08 01:02:192022-03-08 01:17:05Manufacturing started for Hailie® for Symbicort® sensors with physiological parameters
Biomedical projects at the cutting edge of innovation will receive a $25m cash injection, in a boost for next-gen medicine including stem cell research, new treatments for autism and a technology that allows medicine to be taken through the skin. The $25m investment through the federal Biomedical Translation Fund will potentially benefit thousands of Australians […]
An Australian backed and enabled “smart” orthopaedic knee implant set to revolutionise knee replacements has been given marketing authorisation by the US Food and Drug Administration. The canturioTMte device has been backed by Melbourne-based healthcare investment firm, BioScience Managers (BSM) to assist with the aggregation of patient data for software developed by Melbourne-based healthcare informatics […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-11-12 00:42:552021-11-12 00:42:55AUSSIE-BACKED “SMART KNEE” TECHNOLOGY TO HIT THE GROUND RUNNING IN THE US MARKET
Link to full article Cambridge, UK, 11 October 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, continues to build a strong patent portfolio protecting its proprietary Arestat™ technology. Arecor is pleased to announce that its European patent EP2457590 on polysaccharide vaccines has been successfully upheld following opposition […]
The West Australian Tue, 19 October 2021 3:13PM WA-based Hall and Prior will be the first Australian aged care provider to roll-out a new “world-first” platform designed to reduce human error in the sector. The software developed by Australian company Humanetix automates administration work to free-up time for carers by up to 96 minutes per […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-10-24 02:07:582021-10-24 02:07:58WA aged-care provider Hall and Prior to launch ‘world-first’ administration platform
Link to full article Humanetix is set for global expansion following a partnership with the international investment firm BioScience Managers (BSM). Humanetix’s main product ACE, is point-of-care documentation, decision-support and clinical workflow IT system that supports staff care delivery for residential aged care residents. The technology has been part of a 2-year trial conducted by the […]
Link to full article August 30, 2021— Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Canary Medical, a medical data company, today announced U.S. Food and Drug Administration (FDA) DeNovo classification grant and authorization to market the tibial extension for PersonaIQ®, the world’s first and only smart knee cleared […]
/wp-content/uploads/2018/01/BSM_logo.png00victoria/wp-content/uploads/2018/01/BSM_logo.pngvictoria2021-09-17 03:28:102021-09-17 03:43:03Zimmer Biomet and Canary Medical Announce FDA De Novo Classification Grant and Authorization to Market the World’s First and Only Smart Knee Implant
Link to full article Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to recovery through day 60 in all patients who received study drug (a pre-specified supplementary analysis of the primary endpoint) Statistically significant 56% relative risk reduction in […]
Adherium submits US FDA 510(k) application for Ellipta® inhaler users to connect to Hailie platform with physiological parameters
/in Adherium, UncategorisedLink to full article Melbourne, Australia – 7 March 2022: Adherium (ASX: ADR), a leader in respiratory eHealth, remote monitoring, and data management solutions, announces the submission to the US Food and Drug Administration (FDA) of a 510(k) clearance to market application to connect Ellipta® inhaler users with its new, next generation Hailie® sensor with […]
Adherium announces the appointment of Lou Panaccio to the Board with Matt McNamara stepping down
/in Adherium, BioSciences ManagersLink to Full Article Melbourne, Australia – 25 February 2022: Adherium Limited (“Adherium” or “the Company”; ASX: ADR), a provider of integrated digital health solutions and a world leader in connected respiratory medical devices, announces the appointment of Mr Lou Panaccio as a Non-executive director of Adherium with Mr Matthew McNamara stepping down as a […]
Manufacturing started for Hailie® for Symbicort® sensors with physiological parameters
/in Adherium, UncategorisedLink to article Melbourne, Australia – 11 February 2022: Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, is pleased to announce it has completed the first production run of the next generation Hailie® sensors with physiological parameters for monitoring Asthma and Chronic Obstructive Pulmonary Disease (COPD) medication use. […]
$25m spur for vital bio-med projects
/in Acrux, Cynata, Industry News, UncategorisedBiomedical projects at the cutting edge of innovation will receive a $25m cash injection, in a boost for next-gen medicine including stem cell research, new treatments for autism and a technology that allows medicine to be taken through the skin. The $25m investment through the federal Biomedical Translation Fund will potentially benefit thousands of Australians […]
AUSSIE-BACKED “SMART KNEE” TECHNOLOGY TO HIT THE GROUND RUNNING IN THE US MARKET
/in BioSciences Managers, Canary Medical, UncategorisedAn Australian backed and enabled “smart” orthopaedic knee implant set to revolutionise knee replacements has been given marketing authorisation by the US Food and Drug Administration. The canturioTMte device has been backed by Melbourne-based healthcare investment firm, BioScience Managers (BSM) to assist with the aggregation of patient data for software developed by Melbourne-based healthcare informatics […]
ARECOR’S POLYSACCHARIDE VACCINE PATENT UPHELD
/in Arecor, BioSciences Managers, UncategorisedLink to full article Cambridge, UK, 11 October 2021: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, continues to build a strong patent portfolio protecting its proprietary Arestat™ technology. Arecor is pleased to announce that its European patent EP2457590 on polysaccharide vaccines has been successfully upheld following opposition […]
WA aged-care provider Hall and Prior to launch ‘world-first’ administration platform
/in BioSciences Managers, Humanetix, UncategorisedThe West Australian Tue, 19 October 2021 3:13PM WA-based Hall and Prior will be the first Australian aged care provider to roll-out a new “world-first” platform designed to reduce human error in the sector. The software developed by Australian company Humanetix automates administration work to free-up time for carers by up to 96 minutes per […]
Humanetix and BioScience Managers partner to launch tech platform globally
/in BioSciences Managers, HumanetixLink to full article Humanetix is set for global expansion following a partnership with the international investment firm BioScience Managers (BSM). Humanetix’s main product ACE, is point-of-care documentation, decision-support and clinical workflow IT system that supports staff care delivery for residential aged care residents. The technology has been part of a 2-year trial conducted by the […]
Zimmer Biomet and Canary Medical Announce FDA De Novo Classification Grant and Authorization to Market the World’s First and Only Smart Knee Implant
/in BioSciences Managers, Canary Medical, UncategorisedLink to full article August 30, 2021— Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Canary Medical, a medical data company, today announced U.S. Food and Drug Administration (FDA) DeNovo classification grant and authorization to market the tibial extension for PersonaIQ®, the world’s first and only smart knee cleared […]
CalciMedica Reports Topline Data from the AuxoraTM CARDEA Phase 2 COVID-19 Pneumonia Clinical Trial
/in BioSciences Managers, CalcimedicaLink to full article Reduction in time to recovery through day 60 in patients with moderate and severe respiratory failure (primary endpoint analysis) Statistically significant reduction in time to recovery through day 60 in all patients who received study drug (a pre-specified supplementary analysis of the primary endpoint) Statistically significant 56% relative risk reduction in […]